HRP20090679T1 - Upotreba oksikodona za liječenje organske boli - Google Patents
Upotreba oksikodona za liječenje organske boli Download PDFInfo
- Publication number
- HRP20090679T1 HRP20090679T1 HR20090679T HRP20090679T HRP20090679T1 HR P20090679 T1 HRP20090679 T1 HR P20090679T1 HR 20090679 T HR20090679 T HR 20090679T HR P20090679 T HRP20090679 T HR P20090679T HR P20090679 T1 HRP20090679 T1 HR P20090679T1
- Authority
- HR
- Croatia
- Prior art keywords
- pain
- oxycodone
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
Links
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 title claims abstract 22
- 229960002085 oxycodone Drugs 0.000 title claims abstract 22
- 208000009935 visceral pain Diseases 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 24
- 239000003814 drug Substances 0.000 claims abstract 16
- 208000002193 Pain Diseases 0.000 claims abstract 12
- 238000004519 manufacturing process Methods 0.000 claims abstract 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 18
- 229940079593 drug Drugs 0.000 claims 11
- 229960005181 morphine Drugs 0.000 claims 9
- 239000002552 dosage form Substances 0.000 claims 4
- 239000004925 Acrylic resin Substances 0.000 claims 2
- 229920000178 Acrylic resin Polymers 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 208000000112 Myalgia Diseases 0.000 claims 2
- 230000003187 abdominal effect Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000013465 muscle pain Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010004663 Biliary colic Diseases 0.000 claims 1
- 208000019399 Colonic disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000015877 Duodenal disease Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000037767 Gallbladder pain Diseases 0.000 claims 1
- 206010019705 Hepatic pain Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035623 Pleuritic pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010038490 Renal pain Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 208000018595 duodenum disease Diseases 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Upotreba oksikodona ili njegove farmaceutski prihvatljive soli za proizvodnju lijeka za liječenje organske boli. Patent sadrži još 19 patentnih zahtjeva.
Claims (20)
1. Upotreba oksikodona ili njegove farmaceutski prihvatljive soli za proizvodnju lijeka za liječenje organske boli.
2. Upotreba prema zahtjevu 1, naznačena time da se oksikodon ili njegova farmaceutski prihvatljiva sol upotrebljava za proizvodnju lijeka za liječenje akutne organske boli.
3. Upotreba prema bilo kojem zahtjevu 1 ili 2, naznačena time da se oksikodon ili njegova farmaceutski prihvatljiva sol upotrebljava za proizvodnju lijeka za selektivno liječenje organske boli.
4. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek oralni oblik davanja koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol.
5. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je organska bol bol kod pankreatitisa, porođajna bol, bol nastala operacijom u području abdomena povezana s tankim crijevom, bol kod iritabilnog sindroma crijeva, abdominalna bol kod neulkusne dispepsije, ili kod dismenoreje, bol jetre, bol bubrega, bol u epigastriju, pleuralna bol, bolan bilijarni kolik ili bol kod apendicitisa.
6. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je organska bol posljedica bolesti abdomena, dvanaestopalačnog crijeva ili debelog crijeva, Kronove bolesti, boli žučne vrećice, teške menstrualne boli ili odgovarajućih post operativnih bolnih stanja.
7. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u obliku davanja koji se daje jednom dnevno, dvaput dnevno, triput dnevno, ili četiri puta dnevno.
8. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek u obliku davanja koji se daje jednom dnevno koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u količini od oko 10 mg.
9. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek u obliku davanja koji se daje dvaput dnevno koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u količini od oko 5 mg.
10. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek u obliku davanja koji se daje triput dnevno koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u količini od oko 5 mg.
11. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek u obliku davanja koji se daje četiri puta dnevno koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u količini od oko 5 mg.
12. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek u obliku davanja s produljenim otpuštanjem koji ne sadrži više od 40 mg oksikodona ili njegove farmaceutski prihvatljive soli, poželjno ne više od 30 mg oksikodona ili njegove farmaceutski prihvatljive soli ili još poželjnije ne više od 10 mg oksikodona ili njegove farmaceutski prihvatljive soli.
13. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek formulacija za jedan entitet.
14. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek oralni oblik davanja koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u doziranju koje je manje od odgovarajućeg doziranja morfija potrebnog za postizanje istog terapeutskog učinka.
15. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je lijek oralni oblik davanja koji sadrži oksikodon ili njegovu farmaceutski prihvatljivu sol u doziranju koje pruža značajno bolji učinak od oralnog ekvipotentnog doziranja morfija, gdje se ekvipotencija odnosi na liječenje kožnih i mišićnih boli.
16. Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time se oksikodon ili njegova farmaceutski prihvatljiva sol primjenjuju oralno u doziranju koje je manje od ekvipotentnog doziranja morfija, gdje se ekvipotencija odnosi na liječenje kožnih i mišićnih boli.
17. Upotreba prema zahtjevu 16, naznačena time da je odnos doziranja oksikodona prema doziranju morfija manji od 1:2, poželjno manji od 1:2.5, poželjnije manji od 1:3 i najpoželjnije manji od 1:4.
18. Upotreba prema bilo kojem zahtjevu od 1 do 6, naznačena time da je lijek u oralnom obliku davanja s kontroliranim otpuštanjem za kontrolu organske boli kod ljudskih pacijenata, a oblik davanja sadrži:
a) od 5 mg do 80 mg oksikodona ili njegove soli;
b) učinkovitu količinu matrice akrilne smole za produljeno otpuštanje, navedena matrica akrilne smole je odabrana na takav način da formulacija pruža značajne pH-neovisne karakteristike otapanja in-vitro;
c) farmaceutski razrjeđivač.
19. Upotreba oksikodona ili njegove farmaceutski prihvatljive soli za proizvodnju lijeka za liječenje organske boli u pacijenta koji je već bio oralno liječen morfijem ili njegovom soli, gdje je oksikodon ili njegova farmaceutski prihvatljiva sol oralno primjenjuje u količini manjoj od 50% težine morfija ili njegove soli nakon što je liječenje s morfijem prekinuto.
20. Upotreba prema zahtjevu 19, naznačena time da se oksikodon ili njegova farmaceutski prihvatljiva sol oralno primjenjuju u količini manjoj od 45% težine morfija ili njegove soli, poželjno manje od 40% težine, poželjnije manje od 35% težine, još poželjnije manje od 30% težine i najpoželjnije 25% težine morfija ili njegove soli.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64549005P | 2005-01-18 | 2005-01-18 | |
| PCT/EP2006/050252 WO2006077212A1 (en) | 2005-01-18 | 2006-01-17 | Use of oxycodone for treating visceral pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090679T1 true HRP20090679T1 (hr) | 2010-01-31 |
Family
ID=35871217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090679T HRP20090679T1 (hr) | 2005-01-18 | 2009-12-18 | Upotreba oksikodona za liječenje organske boli |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20080200493A1 (hr) |
| EP (1) | EP1838318B1 (hr) |
| JP (1) | JP5049139B2 (hr) |
| KR (10) | KR20210131450A (hr) |
| CN (1) | CN101106996B (hr) |
| AP (1) | AP2249A (hr) |
| AR (1) | AR052880A1 (hr) |
| AT (2) | ATE446092T1 (hr) |
| AU (1) | AU2006207498B2 (hr) |
| BR (1) | BRPI0606247A2 (hr) |
| CA (1) | CA2595043C (hr) |
| CY (1) | CY1109660T1 (hr) |
| DE (2) | DE602006009899D1 (hr) |
| DK (2) | DK1838318T3 (hr) |
| EA (1) | EA013544B1 (hr) |
| ES (1) | ES2333901T3 (hr) |
| HK (1) | HK1107933A1 (hr) |
| HR (1) | HRP20090679T1 (hr) |
| IL (1) | IL184530A (hr) |
| ME (1) | ME01066B (hr) |
| MX (1) | MX2007007207A (hr) |
| MY (1) | MY144471A (hr) |
| NO (1) | NO338968B1 (hr) |
| NZ (1) | NZ555852A (hr) |
| PL (1) | PL1838318T3 (hr) |
| PT (1) | PT1838318E (hr) |
| RS (1) | RS51069B (hr) |
| SI (1) | SI1838318T1 (hr) |
| TW (1) | TWI432196B (hr) |
| UA (1) | UA85471C2 (hr) |
| WO (1) | WO2006077212A1 (hr) |
| ZA (1) | ZA200705231B (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS20080200A (en) | 2005-11-14 | 2009-07-15 | Rinat Neuroscience Corp., | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| ES2689322T3 (es) | 2008-03-04 | 2018-11-13 | Teva Pharmaceuticals International Gmbh | Métodos para tratar el dolor crónico |
| US9005660B2 (en) | 2009-02-06 | 2015-04-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| NZ603579A (en) | 2009-06-24 | 2014-02-28 | Egalet Ltd | Controlled release formulations |
| WO2011024113A1 (en) | 2009-08-28 | 2011-03-03 | Rinat Neuroscience Corporation | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
| BR112013029959A8 (pt) | 2011-05-20 | 2021-09-08 | Alderbio Holdings Llc | Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante |
| EP3662932B1 (en) | 2011-05-20 | 2021-04-07 | H. Lundbeck A/S | Anti-cgrp compositions and use thereof |
| EP2709662B1 (en) | 2011-05-20 | 2019-07-31 | AlderBio Holdings LLC | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| LT3119431T (lt) | 2014-03-21 | 2024-03-12 | Teva Pharmaceuticals International Gmbh | Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| KR20210094513A (ko) | 2018-11-19 | 2021-07-29 | 재즈 파마슈티칼즈 아일랜드 리미티드 | 알코올-내성 약물 제형 |
| TWI839435B (zh) | 2019-01-08 | 2024-04-21 | 丹麥商Ｈ．朗德貝克公司 | 使用抗cgrp 抗體急性治療和快速治療頭痛 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656295A (en) * | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5478577A (en) * | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
| US5958459A (en) * | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
| IL110014A (en) * | 1993-07-01 | 1999-11-30 | Euro Celtique Sa | Solid controlled-release oral dosage forms of opioid analgesics |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| IL126203A (en) * | 1996-03-25 | 2002-12-01 | Lilly Co Eli | A synergistic painkiller that contains olenzapine and another painkiller |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US6992193B2 (en) * | 2003-06-10 | 2006-01-31 | Adolor Corporation | Sulfonylamino phenylacetamide derivatives and methods of their use |
-
2006
- 2006-01-05 TW TW095100458A patent/TWI432196B/zh not_active IP Right Cessation
- 2006-01-09 MY MYPI20060082A patent/MY144471A/en unknown
- 2006-01-17 DK DK06700652T patent/DK1838318T3/da active
- 2006-01-17 SI SI200630538T patent/SI1838318T1/sl unknown
- 2006-01-17 UA UAA200708142A patent/UA85471C2/ru unknown
- 2006-01-17 KR KR1020217034339A patent/KR20210131450A/ko not_active Application Discontinuation
- 2006-01-17 EP EP06700652A patent/EP1838318B1/en active Active
- 2006-01-17 KR KR1020237042001A patent/KR20230170811A/ko active Application Filing
- 2006-01-17 AU AU2006207498A patent/AU2006207498B2/en active Active
- 2006-01-17 AP AP2007004057A patent/AP2249A/xx active
- 2006-01-17 AT AT06700652T patent/ATE446092T1/de active
- 2006-01-17 KR KR1020227041445A patent/KR20220165797A/ko not_active Application Discontinuation
- 2006-01-17 PT PT06700652T patent/PT1838318E/pt unknown
- 2006-01-17 RS RSP-2009/0553A patent/RS51069B/sr unknown
- 2006-01-17 DE DE602006009899T patent/DE602006009899D1/de active Active
- 2006-01-17 MX MX2007007207A patent/MX2007007207A/es active IP Right Grant
- 2006-01-17 WO PCT/EP2006/050252 patent/WO2006077212A1/en active Application Filing
- 2006-01-17 BR BRPI0606247-4A patent/BRPI0606247A2/pt not_active Application Discontinuation
- 2006-01-17 CN CN2006800024739A patent/CN101106996B/zh active Active
- 2006-01-17 KR KR1020177004572A patent/KR20170021905A/ko not_active Application Discontinuation
- 2006-01-17 DE DE202006019887U patent/DE202006019887U1/de not_active Expired - Lifetime
- 2006-01-17 ME MEP-2009-352A patent/ME01066B/me unknown
- 2006-01-17 EA EA200701541A patent/EA013544B1/ru not_active IP Right Cessation
- 2006-01-17 PL PL06700652T patent/PL1838318T3/pl unknown
- 2006-01-17 KR KR1020087029312A patent/KR20080106991A/ko active Application Filing
- 2006-01-17 KR KR1020077018905A patent/KR20070100368A/ko not_active Application Discontinuation
- 2006-01-17 NZ NZ555852A patent/NZ555852A/en unknown
- 2006-01-17 US US11/814,020 patent/US20080200493A1/en not_active Abandoned
- 2006-01-17 KR KR1020127011713A patent/KR20120089710A/ko not_active Application Discontinuation
- 2006-01-17 KR KR1020197035201A patent/KR20190135557A/ko not_active Application Discontinuation
- 2006-01-17 KR KR1020147018838A patent/KR20140091782A/ko not_active Application Discontinuation
- 2006-01-17 KR KR1020207031796A patent/KR20200128451A/ko not_active Application Discontinuation
- 2006-01-17 ES ES06700652T patent/ES2333901T3/es active Active
- 2006-01-17 CA CA2595043A patent/CA2595043C/en active Active
- 2006-01-17 JP JP2007550797A patent/JP5049139B2/ja not_active Expired - Fee Related
- 2006-01-18 AR ARP060100177A patent/AR052880A1/es unknown
-
2007
- 2007-03-09 AT AT0014807U patent/AT9895U1/de not_active IP Right Cessation
- 2007-07-02 ZA ZA200705231A patent/ZA200705231B/xx unknown
- 2007-07-10 IL IL184530A patent/IL184530A/en active IP Right Grant
- 2007-07-24 DK DK200700207U patent/DK200700207U3/da not_active IP Right Cessation
- 2007-08-14 NO NO20074174A patent/NO338968B1/no not_active IP Right Cessation
- 2007-12-12 HK HK07113550.8A patent/HK1107933A1/xx unknown
-
2009
- 2009-12-16 CY CY20091101308T patent/CY1109660T1/el unknown
- 2009-12-18 HR HR20090679T patent/HRP20090679T1/hr unknown
-
2014
- 2014-10-15 US US14/515,216 patent/US9271974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20090679T1 (hr) | Upotreba oksikodona za liječenje organske boli | |
| Edaravone Acute Infarction Study Group | Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters | |
| JP2008526927A5 (hr) | ||
| TWI455723B (zh) | 納曲酮及安非他酮於治療超重或肥胖病患之用途 | |
| RU2011110765A (ru) | Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения | |
| CN102204904B (zh) | 左旋奥拉西坦在制备预防或治疗认知功能障碍药物中的应用 | |
| JP2019517542A5 (hr) | ||
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| JP2007302657A (ja) | 痙症の兆候および症候の緩和方法 | |
| AU2018357350B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2018507243A5 (hr) | ||
| RU2008102911A (ru) | Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы | |
| BR112013010829B1 (pt) | Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| WO2007120485A2 (en) | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| CN100355450C (zh) | 秦川通痹片 | |
| RU2007101695A (ru) | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения | |
| RU2261098C2 (ru) | Перорально распадающаяся композиция, содержащая миртазапин | |
| Toma et al. | Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. | |
| JPWO2021202419A5 (hr) | ||
| ES2668943T3 (es) | Composición farmacéutica para tratar eyaculación precoz y método de tratamiento de la eyaculación precoz | |
| WO2001049269A1 (en) | Sustained-releasing anthelmintic compositions comprising praziquantel | |
| CN102648915B (zh) | 一种治疗或预防神经病理性疼痛的药物组合物 |